Abstract
Recent advances in targeted radiotherapy offer a new approach for the management of metastatic bone pain. This paper will review the scientific basis for radionuclide therapy and will examine the evidence for clinical efficacy. The therapeutic potential of targeted radiotherapy can only be appreciated by comparison with established treatments. Alternative treatment options will, therefore, be discussed, to bring the potential advantages and hazards of targeted radiotherapy into perspective and to define its place in routine management.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Adami S, Salvagno G, Guarrera G, Bianchi G, Dorizzi R, Rosini S (1985) Dichloromethylene disphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 134:1152–1154
Blake GM, Zivanovic MA, McEwan AJ, Ackery DM (1986) Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12:447–454
Blake GM, Zivanovic MA, McEwan AJ, Batty VB, Ackery DM (1987) Sr-89 radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma. Bur J Nucl Med 13:41–46
Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJ, Ackery DM (1988) Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med 29:549–557
Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL (1984) Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 57:323–327
Burnet NG, Williams G, Howard N (1990) Phosphorus-32 for intractable bony pain from carcinoma of the prostate. Clin Oncol 2:220–223
Carey PO, Lippert MC (1988) Treatment of painful prostatic bone metastases with oral editronate disodium. J Urol 32:403–407
Cole DJ (1989) A radiomised trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases. Clin Oncol 1: 59–62
Coleman RE, Rubens RD (1987) The clinical course of bone metastases in breast cancer. Br J Cancer 55:61–66
Davies J, Trask C, Souhami RL (1979) Effect of mithramycin on widespread painful bone metastases in cancer of the breast. Cancer Treat Rep 63:1835–1838
Eary JF, Collins C, Appelbaum FR, Nemiroff C, Ferency S, Richter KY, Gordon BE (1990) Sm-153 EDTMP treatment of hormone refractory prostate carcinoma. J Nucl Med 31:5;755
Eisenhut M (1984) Iodine-131 labeled diphosphonates for the palliative treatment of bone metastases: organ distribution and kinetics of I-131 BDP3 in rats. J Nucl Med 25:1356–1361
Eisenhut M, Berberich R, Kimmig B, Oberhausen E (1986) Iodine-131 labeled diphosphonates for palliative treatment of bone metastases: II. Preliminary clinical results with iodine-131 BDP3. J Nucl Med 27:1255–1261
Elomaa I, Blomqvist C, Porkka L (1985) Diphosphonates for skeletal metastases. Lancet 11:1063
Evans PJD (1990) Opioids in the treatment of cancer pain. In: Doyle D (ed) Royal Society of Medicine Services International Congress and Symposium Series No 146. Royal Society of Medicine Services Ltd
Firusian N, Mellin P, Schmidt CG (1976) Results of strontium-89 therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urol 116:764–768
Galasko CSB (1976) Mechanisms of bone destruction in the development of skeletal metastases. Nature 263:507–508
Gennari C, Francini G, Chierichetti SM, Nami R, Gonelli S, Poilini M (1989) Salmon calcitonin treatment in bone metastases. Curr Ther Res 45:804–812
Goeckler WE, Edwards B, Volkert WA, Holmes RA, Simon J, Wilson D (1987) Skeletal localisation of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 28:495–504
Hall EJ (1978) Radiobiology for the radiologist. Harper & Row, Philadelphia, p 145
Hertz S (1950) Modifying effect of steroid hormone therapy on human neoplastic disease as judged by radioactive phosphorus (P32). J Clin Invest 29:821
Hoefnagel CA, Voute PA, de Kraker J, Marcuse HR (1987) Radionuclide diagnosis and therapy of nueroectodermal tumours using 1-131 metaiodobenzylguanidine. J Nucl Med 28:308–314
Hoskin PJ (1991) Radiotherapy in the management of bone metastases. In: Rubens RD, Fogelman I (eds) Bone metastases: diagnosis and treatment. Springer, Berlin Heidelberg New York
Hoskin PJ, Ford HT, Harmer CL (1989) Hemibody irradiation for metastatic bone pain in two histologically distinct groups of patients. Clin Oncol 1:67–69
Hoyan DL (1988) Damage and protection of the human gastric mucosa. Am J Med 84[2A]:35–40
Kasi LP, Fossella F, Holoye P, Podoloff D, Kim E, Crane J, Cordon EE (1991) Evaluation of multiple dose Sm-153-EDTMP for bone pain palliation in cancer patients. Proc. 7th international symposium of radiopharmacology. Boston, Mass, p 11
Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan AJ, Macleod PM, Zivanovic MA (1991) Strontium-89 therapy for pain palliation in prostatic skeletal malignancy. Br J Radiol 64:816–822
Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, Porter AT, Zivanovic MA (1991) A prospective randomised double blind corssover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Bur J Cancer 27:954–958
Lewington VJ, Zivanovic MA, Tristam M, McEwan AJ, Ackery DM (1991b) I-131 mlBG therapy for malignant phaeochromocytoma. J Nucl Biol Med 35:280–283
Lewington VJ, Bolger PJ, Dearnaley DP, Kirk D, Quilty PM, Yardley J, Zivanovic MA (1992) Is strontium-89 an effective alternative to radiotherapy for prostatic metastases? Nucl Med Commun [Abs] 13:211–212 (abstr)
Masud T, Slevin ML (1989) Pamidronate to reduce bone pain in a normocalcaemic patient with disseminated prostatic carcinoma. Lancet I:1021–1022
Maxfield JR, Maxfield JCS, Maxfield WS (1958) The use of radioactive phosphorus and testosterone in metastatic bone lesions from breast and prostate. South Med J 51:937–327
Maxon HR, Schroder LE, Thomas SR (1990) Re-186[Sn]HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone resistant prostate cancer. Radiology 176:155–159
Maxon III HR, Schroder LE, Hertzberg VS, Thomas SR, Englaro BE, Samaratunga R, Smith H, Moulton JS, Williams CC, Ehrhardt GJ, Schneider HJ (1991) Rhenium-186[Sn]HEDP for treatment of painful osseous metastases: results of a double blind crossover comparison with placebo. J Nucl Med 32:1877–1881
McEwan AJB, Porter A, Venner P, Amyotte G (1990) An evaluation of the safety and efficacy of treatment with Sr-89 in patients who have previously received wide field radiotherapy. Antibodies, Immunoconjugates and Radiopharmaceuticals 3[2]:91–98
Merlini G, Parrinello GA, Piccinini L (1990) Long term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. Haematol Oncol 8:23–30
Pecher C (1942) Biological investigations with radioactive calcium and strontium. Preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. University of California Publications in Pharmacology 2:117–149
Podoloff DA, Kasi LP, Kim BE, Fossella F, Bhadkamkar VA (1991) Evaluation of Sm-153 EDTMP as a bone imaging agent during a therapeutic trial (abstr). J Nucl Med 32:918
Price P, Hoskin PJ, Easton P, Austin D, Palmer SG, Yarnold JR (1986) Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bone metastases. Radiother Oncol 6:247–255
Robinson RG, Spicer JA, Preston DF, Wegst AV, Martin NL (1987) Treatment of metastatic bone pain with strontium-89. Int J Rad Appl Instrum [B] 1:219–222
Roth A, Kolaric K (1986) Analgesic activity of calcitonin in patients with painful osteolytic metastases of breast cancer. Results of a controlled randomized study. Oncology 43:283–287
Silberstein EB, Williams C (1985) Strontium 89 therapy for the pain of osseous metastases. J Nucl Med 26:345–348
Siris ES, Hyman GA, Canfield RE (1983) Effects of dichloromethylene bisphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 74:401–406
Stoll BA (1983) Natural history, prognosis and staging of bone metastases. In: Stoll BA, Parbhoo S (eds) Bone metastases: monitoring and treatment. Raven, New York, pp 1–4
Tong ECK (1971) Parathormone and P-32 therapy in prostatic cancer with bone metastases. Radiology 98:343–351
Turner JH, Claringbold PG (1991) A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphate. Eur J Cancer 27:1084–1086
Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, Claringbold PG (1989) Samarium-153 EDTMP of disseminated skeletal metastasis. Eur J Nucl Med 15:784–795
Twycross RG, Fairfield S (1982) Pain in far advanced cancer. Pain 14:303–310
van Holten-Verzantvoort AT, Bijvoet OLM, Hermens J (1987) Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment. Lancet II:983–985
Ventafridda V (1989) Continuing care: a major issue in pain management. Pain 36:137–144
Ventafridda V, Sbanotto A, De Conno F (1990) Review article: pain in prostate cancer. Palliative Medicine 4:173–184
World Health Organisation (1986) Cancer pain relief. World Health Organisation, Geneva
Zonnenberg BA, de Klerk JMH, van Rijk PP, Quirijnen JMSP, van het Schip AD, van Dijk A, ten Kroode NFJ (1991) Re-186HEDP for treatment of painful bone metastases in patients with metastatic prostate or breast cancer. Preliminary results (abstract). J Nucl Med 32:1082
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lewington, V.J. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 20, 66–74 (1993). https://doi.org/10.1007/BF02261248
Issue Date:
DOI: https://doi.org/10.1007/BF02261248